Targeted fibrinogen concentrate use in severe traumatic haemorrhage.


Journal

Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine
ISSN: 1441-2772
Titre abrégé: Crit Care Resusc
Pays: Netherlands
ID NLM: 100888170

Informations de publication

Date de publication:
Sep 2019
Historique:
entrez: 30 8 2019
pubmed: 30 8 2019
medline: 14 9 2019
Statut: ppublish

Résumé

Fibrinogen is one of the first coagulation factors to be depleted during traumatic haemorrhage, and evidence suggests hypofibrinogenaemia leads to poor outcomes. A number of fibrinogen replacement products are currently available, with no clear consensus on the ideal product to use in severe traumatic haemorrhage. We hypothesised that it will be possible to rapidly administer fibrinogen concentrate (FC) guided by rotational thromboelastometry (ROTEM) FIBTEM A5 in patients presenting with trauma haemorrhage. We examined 36 consecutive patients with trauma admitted to a level 1 trauma centre in Australia who received FC as part of their initial resuscitation. ROTEM analysis was conducted at various time points from emergency department (ED) admission to 48 hours after admission. The primary outcome was time to administration of FC after identification of hypofibrinogenaemia using ROTEM FIBTEM A5. Data were collected on quantity and timing of product transfusion, demographics, Injury Severity Score and laboratory values of coagulation. Spearman rank order correlation was used to determine the correlation between FIBTEM A5 and Clauss fibrinogen (FibC). Thirty-six patients received FC as their initial form of fibrinogen replacement during the study. Patients were hypofibrinogenaemic by both FIBTEM A5 (6 mm) and FibC (1.7 g/L) on presentation to the ED. It took a median of 22 minutes (IQR, 17-30 minutes) from time of a FIBTEM A5 analysis to FC administration. Both parameters increased significantly ( This study suggests that administration of FC represents a rapid and feasible method to replace fibrinogen in severe traumatic haemorrhage. However, the optimal method for replacing fibrinogen in traumatic haemorrhage is controversial and large multicentre randomised controlled trials are needed to provide further evidence. This study provided baseline data to inform the design of further clinical trials investigating fibrinogen replacement in traumatic haemorrhage.

Identifiants

pubmed: 31462204

Substances chimiques

Fibrinogen 9001-32-5

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

171-178

Auteurs

Jacqueline A Seebold (JA)

Gold Coast Health, Gold Coast, QLD, Australia. jacqueline.seebold@health.qld.gov.au.

Don Campbell (D)

Gold Coast Health, Gold Coast, QLD, Australia.

Elizabeth Wake (E)

Gold Coast Health, Gold Coast, QLD, Australia.

Kerin Walters (K)

Gold Coast Health, Gold Coast, QLD, Australia.

Debbie Ho (D)

Gold Coast Health, Gold Coast, QLD, Australia.

Erick Chan (E)

Gold Coast Health, Gold Coast, QLD, Australia.

Andrew C Bulmer (AC)

Griffith University, Gold Coast, QLD, Australia.

Martin Wullschleger (M)

Gold Coast Health, Gold Coast, QLD, Australia.

James Winearls (J)

Gold Coast Health, Gold Coast, QLD, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH